Frank Jaschinski

Company: Secarna

Job title: Chief Scientific Officer

Bio:

Frank joined Secarna in 2015 as its Chief Scientific Officer. He is an expert in the discovery and development of antisense oligonucleotides. Frank’s therapeutic expertise is rooted in the fields of oncology and metabolic diseases. He has profound knowledge in conceptualizing, developing, and evaluating ASO-based, targeted therapies, playing a central role in establishing new, high-value ASO pipelines in the course of his career.
Before joining Secarna, Frank worked in scientific leadership positions at Antisense Pharma/Isarna Therapeutics and The Genetics Company. Frank is an active contributor to the international scientific and biopharmaceutical discovery and development community and his and his team’s work is recognized at international conferences and in major peer-reviewed publications.

Seminars:

Modulation of the Tumor Microenvironment Using Antisense Oligonucleotides 11:30 am

Tumors actively shape their microenvironment to promote angiogenesis, metastasis, and immune evasion, creating conditions that support their growth and resistance to therapy Neuropilin-1 (NRP1) is broadly expressed across multiple cell types within the tumor microenvironment, where it simultaneously facilitates these pro-tumorigenic processes Antisense oligonucleotides (ASOs) designed to silence NRP1 expression effectively reduce its levels in key cellular compartments, leading to potent…Read more

day: Conference Day One